Endo International (NASDAQ:ENDP) (TSE:ENL) was upgraded by research analysts at Vetr from a “buy” rating to a “strong-buy” rating in a report issued on Tuesday. The firm presently has a $8.92 price objective on the stock. Vetr‘s price target would indicate a potential upside of 13.63% from the company’s previous close.
A number of other research firms also recently weighed in on ENDP. Goldman Sachs Group initiated coverage on Endo International in a report on Thursday, September 28th. They set a “sell” rating and a $7.00 price objective on the stock. Royal Bank of Canada decreased their price objective on Endo International from $9.00 to $8.00 and set a “sector perform” rating on the stock in a report on Friday, November 10th. Guggenheim initiated coverage on Endo International in a report on Tuesday, December 12th. They set a “neutral” rating and a $8.50 price objective on the stock. Cantor Fitzgerald decreased their price objective on Endo International from $9.00 to $7.00 and set a “neutral” rating on the stock in a report on Friday, November 10th. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and set a $9.00 price objective on shares of Endo International in a report on Sunday, September 17th. Two investment analysts have rated the stock with a sell rating, sixteen have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $11.34.
Shares of Endo International (ENDP) opened at $7.85 on Tuesday. Endo International has a 1 year low of $5.77 and a 1 year high of $17.99. The firm has a market capitalization of $1,740.00, a PE ratio of -0.41, a P/E/G ratio of 2.13 and a beta of 0.59. The company has a debt-to-equity ratio of 10.78, a quick ratio of 0.86 and a current ratio of 1.08.
A number of hedge funds have recently bought and sold shares of ENDP. Blair William & Co. IL bought a new position in Endo International in the 2nd quarter worth approximately $126,000. LMR Partners LLP bought a new position in Endo International in the 3rd quarter worth approximately $148,000. Riverhead Capital Management LLC raised its position in Endo International by 64.4% in the 2nd quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock worth $168,000 after purchasing an additional 5,887 shares during the last quarter. Bank of Hawaii bought a new position in Endo International in the 2nd quarter worth approximately $180,000. Finally, Flinton Capital Management LLC raised its position in Endo International by 64.4% in the 2nd quarter. Flinton Capital Management LLC now owns 20,400 shares of the company’s stock worth $228,000 after purchasing an additional 7,990 shares during the last quarter. Hedge funds and other institutional investors own 93.06% of the company’s stock.
About Endo International
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
What are top analysts saying about Endo International? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Endo International and related companies.